COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,137 Articles (22,693 medRxiv, 8,444 bioRxiv)

Most recent first Previous |  Page 483: Articles 4821-4830  | Next

Predicting COVID-19 case status from self-reported symptoms and behaviors using data from a massive online survey
Srivastava, M., Reinhart, A., Mejia, R.
10.1101/2023.02.03.23285405 — Posted: 2023-02-07
Understanding the Impact of Social Engagement Activities, Health Protocol Maintenance, and Social Interaction on Depression During Covid-19 Pandemic Among Older Americans
Ahmmad, R.
10.1101/2023.02.04.23285479 — Posted: 2023-02-07
Addressing a climate emergency amidst the COVID-19 pandemic: A mixed-methods study on a hospital evacuation during the 2021 European floods
van der Wal, W., Barten, D., Ketelings, L., van Osch, F., Rao, M., Mortelmans, L., Bierens, J.
10.1101/2023.02.02.23285386 — Posted: 2023-02-07
Impact of Immune Evasion, Waning and Boosting on Dynamics ofPopulation Mixing Between a Vaccinated Majority and Unvaccinated Minority
Fisman, D., Amoako, A., Simmons, A., Tuite, A.
10.1101/2023.02.03.23285437 — Posted: 2023-02-07
Olfactory Dysfunction in the COVID-19 Era: An Umbrella Review Focused on Neuroimaging, Management, and Follow-up
Kalantarhormozi, M., Sotoudeh, H., Habibi, M. A., Mahmudpour, M., Shahidi, R., Khalaj, F., Karami, S., Asgarzadeh, A., Baradaran, M., Chichagi, F., Hassanzadeh, S., Farizani Gohari, N. S., Shirforoush Sattari, M., Azimi, A., Dadjou, A., Eskandari, M.
10.1101/2023.02.07.23285588 — Posted: 2023-02-07
Underlying driving forces of the SARS-CoV-2 evolution: immune evasion and ACE2 binding affinity
Ma, W., Fu, H., Jian, F., Cao, Y., Li, M.
10.1101/2023.02.06.527236 — Posted: 2023-02-07
A COVID-19 DNA Vaccine Candidate Elicits Broadly Neutralizing Antibodies Against Multiple SARS-CoV-2 Variants Including the Currently Circulating Omicron BF.5, BF.7, BQ.1 and XBB
Ding, Y., Fan, F., Xu, X., Zhao, G., Zhang, X., Zhao, H., Wang, L., Wang, B., Gao, X.-M.
10.1101/2023.02.06.527382 — Posted: 2023-02-07
Elevated binding and functional antibody responses to SARS-CoV-2 in infants versus mothers
Stoddard, C. I., Sung, K., Yaffe, Z. A., Weight, H., Beaudoin-Bussieres, G., Galloway, J. G., Gantt, S., Adhiambo, J., Begnel, E. R., Ojee, E., Slyker, J., Wamalwa, D., Kinuthia, J., Finzi, A., Matsen, F. A., Lehman, D. A., Overbaugh, J.
10.1101/2023.02.06.527330 — Posted: 2023-02-07
A SARS-CoV-2 vaccine designed for manufacturability results in unexpected potency and non-waning humoral response
Campbell, E., Dobkin, J., Osorio, L., Ramasamy, S., Kumar, R., SantAngelo, D. B., Subbian, S., Denzin, L. K., Anderson, S.
10.1101/2023.02.06.527376 — Posted: 2023-02-07
Heterologous inactivated virus/mRNA vaccination response to BF.7, BQ.1.1, and XBB.1
Zuo, F., Sun, R., Abolhassani, H., Du, L., Wang, Y., Vlachiotis, S., Bertoglio, F., Schubert, M., Rezaei, N., Chavoshzadeh, Z., Guerra, C., Cavalli, A., Andrell, J., Kumagai-Braesch, M., Xue, Y., Cao, Y., Hust, M., F. Robbiani, D., Xie, X., Hammarstrom, L., Marcotte, H., Pan-Hammarstrom, Q.
10.1101/2023.02.02.23285205 — Posted: 2023-02-07

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).